Copper to Zinc Ratio in End Stage Renal Disease Patients Outcome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-08-01

Study Completion Date

2026-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational clinical trial is to Study the impact of copper to zinc ratio on the outcome of ESRD patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy Study of Zinc Supplementation on Anemia, Oxidative Stress and Inflammation in Hemodialysis Patients

NCT02335593

End Stage Renal Disease

COMPLETED PHASE2

Effect of Zinc Suplementation on Serum Hemosystein Level in Hemodialysis Patients

NCT01101217

End Stage Renal Failure

COMPLETED NA

Study to Evaluate Daptomycin Given During Dialysis and After Dialysis

NCT00882557

End-stage Renal Disease Renal Failure Chronic Requiring Hemodialysis

COMPLETED PHASE1

Trial to Optimize Mineral Outcomes in Dialysis Patients

NCT01100723

Secondary Hyperparathyroidism Chronic Kidney Disease

COMPLETED PHASE4

Role of Coenzyme Q10 in Chronic Kidney Disease

NCT05942027

Chronic Kidney Diseases

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

End-stage renal disease (ESRD) carries high morbidity and mortality due to cardiovascular complications, highlighting the need for ongoing research. Trace elements as copper (Cu), and zinc (Zn), are essential for physiological functions, enzyme activity, metabolism, and immune defense. In ESRD patients, Cu and Zn imbalances, with a higher Cu/Zn ratio are linked to greater cardiovascular problems. The relationship between the Cu/Zn ratio and clinical outcomes in ESRD needs more exploration

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ESRD (End Stage Renal Disease) Control Condition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ESRD patients

100 patients on maintainance hemodialysis

No interventions assigned to this group

Control groub

50 Healthy individuals

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ESRD patients including those on maintenance HD

Exclusion Criteria

* Acute kidney injury or rapidly progressive glomerulonephritis, acute infections or active inflammatory conditions as sepsis and autoimmune diseases, liver cirrhosis (Child-Pugh Class B or C), gastrointestinal disorders as inflammatory bowel disease, malabsorption, history of organ transplantation excluding kidney transplantation who may be included in a separate analysis if sufficient numbers are recruited, receiving total parenteral nutrition, Cu or Zn metabolism disorders as Wilson's disease, vitamin complex supplementation or antioxidants within the past 6 months, recent hospitalization within the past 3 months, recent surgery within 3 months, recent blood transfusion \< 3 months, Pregnancy or lactation, Malignancy.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes